Horizon Therapeutics

57 articles about Horizon Therapeutics

• 

  Clinical Catch-Up for June 17-21

  6/24/2019

  Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories.

• Horizon Therapeutics and Nitec Pharma AG Complete Merger and Combine Businesses in an All-stock Transaction

  4/2/2010

• Horizon Therapeutics Said Near Deal to Buy Nitec Pharma AG

  4/1/2010

• Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users

  10/26/2009

• Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer

  6/30/2009

• Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain

  6/2/2009

• Horizon Therapeutics Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California

  3/23/2009

• Horizon Therapeutics Announces Senior Management Appointments

  1/6/2009

• Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints

  12/2/2008

• Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer

  10/9/2008

• Horizon Therapeutics Announces Corporate Relocation to the Chicago Area

  7/31/2008

• Horizon Therapeutics Names Timothy P. Walbert as President and CEO

  7/24/2008

• Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501

  2/11/2008

• Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501

  10/8/2007

• Horizon Therapeutics Scheduled to Present at Upcoming BioPartnering Europe Meeting

  10/5/2007

• Horizon Therapeutics Completes $30 Million Equity Financing to Advance Pipeline of 'GI-Friendly' NSAIDs for Mild-to-Moderate Pain

  7/23/2007

• Horizon Therapeutics Begins Patient Enrollment in Phase 3 Trials for 'GI-Friendly' NSAID

  3/27/2007